165 related articles for article (PubMed ID: 8303945)
1. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany.
Heininger U; Cherry JD; Christenson PD; Eckhardt T; Göering U; Jakob P; Kasper W; Schweingel D; Laussucq S; Hackell JG
Vaccine; 1994 Jan; 12(1):81-6. PubMed ID: 8303945
[TBL] [Abstract][Full Text] [Related]
2. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group.
Blumberg DA; Mink CM; Cherry JD; Johnson C; Garber R; Plotkin SA; Watson B; Ballanco GA; Daum RS; Sullivan B
J Pediatr; 1991 Aug; 119(2):194-204. PubMed ID: 1907317
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of acellular pertussis vaccine, combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederle's diphtheria and tetanus toxoids in two-, four- and six-month-old infants.
Watson B; Cawein A; Mckee BL; Hackell JG
Pediatr Infect Dis J; 1992 Nov; 11(11):930-5. PubMed ID: 1454434
[TBL] [Abstract][Full Text] [Related]
4. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
[TBL] [Abstract][Full Text] [Related]
5. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
[TBL] [Abstract][Full Text] [Related]
6. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.
Morgan CM; Blumberg DA; Cherry JD; Reisinger KS; Blatter MM; Blumer JL; Dekker CL; Stout MG; Christenson PD
Am J Dis Child; 1990 Jan; 144(1):41-5. PubMed ID: 2403747
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
[TBL] [Abstract][Full Text] [Related]
8. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.
Blumberg DA; Mink CM; Cherry JD; Reisinger KS; Blatter MM; Congeni BL; Dekker CL; Stout MG; Mezzatesta JR; Scott JV
J Pediatr; 1990 Jul; 117(1 Pt 1):46-51. PubMed ID: 2196360
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups.
Cherry JD; Mortimer EA; Hackell JG; Scott JV
Dev Biol Stand; 1991; 73():51-8. PubMed ID: 1778334
[TBL] [Abstract][Full Text] [Related]
10. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
Heininger U; Stehr K; Christenson P; Cherry JD
Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
[TBL] [Abstract][Full Text] [Related]
11. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
[TBL] [Abstract][Full Text] [Related]
12. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children.
Glode M; Joffe L; Reisinger K; Blatter M; Plotkin S; Watson B; Grossman L; Asmar B; Berry M; Starobin S
Pediatr Infect Dis J; 1992 Jul; 11(7):530-5. PubMed ID: 1528643
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers.
Black SB; Shinefield HR; Bergen R; Hart C; Kremers R; Lavetter A; Lemesurier J; Morozumi PA; Ray P; Lewis EM; Fireman B; Schwalbe J; Hallam P; Shandling M; Dekker C; Granoff DM; Izu A; Podda A
Pediatr Infect Dis J; 1997 Jan; 16(1):53-8. PubMed ID: 9002102
[TBL] [Abstract][Full Text] [Related]
18. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
Stehr K; Cherry JD
Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
[No Abstract] [Full Text] [Related]
19. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and reactogenicity of Takeda acellular pertussis-component diphtheria-tetanus-pertussis vaccine in 2- and 3-month-old children in Japan.
Kamiya H; Nii R; Matsuda T; Yasuda N; Christenson PD; Cherry JD
Am J Dis Child; 1992 Oct; 146(10):1141-7. PubMed ID: 1415039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
